zetomipzomib (KZR-616) - Kezar
A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE) (clinicaltrials.gov) - Dec 18, 2023 - P2 | N=279 | Recruiting | Sponsor: Kezar Life Sciences, Inc. | Initiation date: May 2023 ➔ Nov 2023 
Trial initiation date • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
http://clinicaltrials.gov/ct2/show/NCT05781750
 
Dec 18, 2023
 
Prev Next